ZA200203229B - 6-Methoxy-2-naphthylacetic acid prodrugs for treating inflammation. - Google Patents
6-Methoxy-2-naphthylacetic acid prodrugs for treating inflammation. Download PDFInfo
- Publication number
- ZA200203229B ZA200203229B ZA200203229A ZA200203229A ZA200203229B ZA 200203229 B ZA200203229 B ZA 200203229B ZA 200203229 A ZA200203229 A ZA 200203229A ZA 200203229 A ZA200203229 A ZA 200203229A ZA 200203229 B ZA200203229 B ZA 200203229B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- composition
- 6mna
- acid
- prodrug
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims description 12
- 230000004054 inflammatory process Effects 0.000 title claims description 12
- 239000000651 prodrug Substances 0.000 title description 32
- 229940002612 prodrug Drugs 0.000 title description 32
- LOWWSYWGAKCKLG-UHFFFAOYSA-N 2-(6-methoxynaphthalen-1-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC2=CC(OC)=CC=C21 LOWWSYWGAKCKLG-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 17
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical group C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 12
- 229960004270 nabumetone Drugs 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000007788 liquid Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- -1 for example Chemical class 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 241000220479 Acacia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 150000002790 naphthalenes Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940087462 relafen Drugs 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16186499P | 1999-10-27 | 1999-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200203229B true ZA200203229B (en) | 2003-07-23 |
Family
ID=22583099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200203231A ZA200203231B (en) | 1999-10-27 | 2002-04-23 | 6-Methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation. |
| ZA200203229A ZA200203229B (en) | 1999-10-27 | 2002-04-23 | 6-Methoxy-2-naphthylacetic acid prodrugs for treating inflammation. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200203231A ZA200203231B (en) | 1999-10-27 | 2002-04-23 | 6-Methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US6525098B1 (no) |
| EP (2) | EP1223926A2 (no) |
| JP (2) | JP2003512424A (no) |
| KR (2) | KR20020043249A (no) |
| CN (2) | CN1413106A (no) |
| AU (2) | AU1576101A (no) |
| BR (2) | BR0015121A (no) |
| CA (2) | CA2387098A1 (no) |
| CZ (2) | CZ20021435A3 (no) |
| HK (2) | HK1048256A1 (no) |
| HU (2) | HUP0203321A2 (no) |
| IL (2) | IL149258A0 (no) |
| MX (2) | MXPA02004355A (no) |
| NO (2) | NO20022000L (no) |
| NZ (2) | NZ518554A (no) |
| PL (2) | PL354895A1 (no) |
| RU (2) | RU2002113657A (no) |
| TW (1) | TWI262791B (no) |
| WO (2) | WO2001030334A2 (no) |
| ZA (2) | ZA200203231B (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262791B (en) * | 1999-10-27 | 2006-10-01 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| US7163958B2 (en) * | 2002-07-03 | 2007-01-16 | Nitromed Inc. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| US7244753B2 (en) * | 2002-07-29 | 2007-07-17 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| WO2010096320A2 (en) * | 2009-02-18 | 2010-08-26 | Bezwada Biomedical, Llc | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers |
| US8062653B2 (en) | 2009-02-18 | 2011-11-22 | Bezwada Biomedical, Llc | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers |
| AU2010232556A1 (en) * | 2009-04-02 | 2011-11-03 | Allergan, Inc. | Prostaglandin E receptor antagonists |
| CN101928227A (zh) * | 2009-12-16 | 2010-12-29 | 天津工业大学 | 6-甲氧基-2-萘乙酸与水杨酰苯胺类化合物的互联体前药制备方法及应用 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3904682A (en) * | 1967-01-13 | 1975-09-09 | Syntex Corp | 2-(6{40 -Methoxy-2{40 -naphthyl)acetic acid |
| US4009197A (en) | 1967-01-13 | 1977-02-22 | Syntex Corporation | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof |
| JPS5441587B1 (no) * | 1969-09-30 | 1979-12-08 | Syntex Corp | |
| DE2051012A1 (en) * | 1970-10-17 | 1972-04-20 | Syntex Corp., Panama | 1,6-methano-(10)-annulenes - with anti-inflammatory analgesic antipyr hypocholesterolaemic and fibrinolytic activity |
| US3978116A (en) * | 1971-11-04 | 1976-08-31 | Syntex Corporation | 2-naphthyl acetic acid derivatives and compositions and methods thereof |
| US3883662A (en) * | 1973-03-29 | 1975-05-13 | Syntex Corp | Method for delaying the onset of, or postponing, parturition |
| US4327022A (en) * | 1973-08-16 | 1982-04-27 | Sterling Drug Inc. | Heterocyclic alkyl naphthols |
| US4420639C1 (en) | 1973-09-11 | 2001-08-21 | Beecham Group Ltd | Aromatic compounds |
| US4061779A (en) | 1973-09-11 | 1977-12-06 | Beecham Group Limited | Naphthalene derivatives having anti-inflammatory activity |
| EP0003074B1 (en) | 1978-01-07 | 1981-04-15 | Beecham Group Plc | Process for the preparation of 4-(6-methoxy-2-naphthyl)butan-2-one and 2-acetyl-3-(6-methoxy-2-naphthyl) propenoic acid esters |
| US4246193A (en) | 1979-11-26 | 1981-01-20 | Syntex Corporation | Process for the resolution of d,1 2-(6-methoxy-2-naphthyl)propionic acid |
| CH641432A5 (de) | 1978-07-19 | 1984-02-29 | Syntex Pharma Int | Verfahren zur aufspaltung von racemischer 6-methoxy-alpha-methyl-2-naphthalinessigsaeure in die optischen antipoden. |
| US4268442A (en) | 1978-11-14 | 1981-05-19 | Sagami Chemical Research Center | Process for preparing aromatic acetic acid |
| EP0011925B1 (en) * | 1978-11-23 | 1982-09-22 | Beecham Group Plc | Naphthalene derivatives, a process for their preparation and their use in anti-inflammatory pharmaceutical compositions |
| IT1109200B (it) | 1979-02-20 | 1985-12-16 | Montedison Spa | Processo per la preparazione di esteri di acidi arilacetici da alfa-alo-alchilarilchetoni |
| US4515811A (en) | 1979-07-06 | 1985-05-07 | Syntex Corporation | Process for the resolution of d,1 2-(6-methoxy-2-naphthyl)propionic acid |
| IT1168387B (it) | 1981-04-01 | 1987-05-20 | Alfa Farmaceutici Spa | Procedimento per la preparazione dell'acido 2-(6-metossi-2-naftil)-propionico |
| US4542237A (en) | 1981-04-30 | 1985-09-17 | Syntex Pharmaceuticals International Limited | Manufacture of alpha-arylalkanoic acids and precursors |
| US4654438A (en) | 1981-04-30 | 1987-03-31 | Syntex Pharmaceuticals International Limited | Manufacture of alpha-arylalkanoic acids and precursors |
| IT1190741B (it) | 1982-03-22 | 1988-02-24 | Blaschim Spa | Procedimento per preparare esteri dell'acido 2-(6'-metossi-2'-naftil)-propionico |
| IT1210947B (it) | 1982-11-03 | 1989-09-29 | Zambon Spa | Procedimento per preparare esteri di acidi arilalcanoici |
| US4723033A (en) | 1982-11-24 | 1988-02-02 | Syntex Pharmaceuticals International Ltd. | Manufacture of optically active α-arylalkanoic acids and precursors thereof |
| IL67445A (en) * | 1982-12-09 | 1985-11-29 | Teva Pharma | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids |
| IT1164319B (it) | 1983-07-27 | 1987-04-08 | Blaschim Spa | Procedimento per la risoluzione dell'acido (+-)2-(6'-metossi-2'-naftil)-propionico |
| JPS6081145A (ja) | 1983-10-11 | 1985-05-09 | Nissan Chem Ind Ltd | ｄ−α−（６−メトキシ−２−ナフチル）プロピオン酸エステルのアルカリ性加水分解による，ｄ−α−（６−メトキシ−２−ナフチル）プロピオン酸の製法 |
| US4661525A (en) | 1984-03-28 | 1987-04-28 | Texaco Inc. | Process for producing lower aliphatic alcohols |
| GB8416638D0 (en) | 1984-06-29 | 1984-08-01 | Beecham Group Plc | Topical treatment and composition |
| ES8700649A1 (es) | 1984-07-11 | 1986-11-16 | Blaschim Spa | Procedimiento para la preparacion de acidos arilalcanoicos |
| US4670586A (en) | 1984-09-12 | 1987-06-02 | Nippon Chemicals Co., Ltd. | Method for the production of α-aryl-alkanoic acid |
| EP0176142B1 (en) | 1984-09-24 | 1991-11-27 | Nobel Chemicals AB | Process for the preparation of aryl alkyl ketones |
| IT1183626B (it) | 1985-05-14 | 1987-10-22 | Vamp Srl | Prodotti polimerici autoestinguenti a base di poliolefine |
| IT1201443B (it) | 1985-07-31 | 1989-02-02 | Zambon Spa | Intermedi per la sintesi di acidi carbossilici |
| JPH064561B2 (ja) | 1986-02-08 | 1994-01-19 | 日本石油化学株式会社 | （置換アリ−ル）カルボン酸の製造方法 |
| CA1286316C (en) | 1986-02-08 | 1991-07-16 | Isoo Shimizu | Method for refining 2-(aryl substituted)-propionic acid or its salt |
| IT1197800B (it) | 1986-08-01 | 1988-12-06 | Zambon Spa | Processo per la sintesi di acidi carbossilici |
| IT1198234B (it) | 1986-12-23 | 1988-12-21 | Zambon Spa | Processo stereoconvergente per la preparazione di acidi carbossilici otticamente attivi |
| US5202495A (en) | 1987-03-26 | 1993-04-13 | Callander Sidney E | Chemical process |
| IT1222013B (it) | 1987-07-10 | 1990-08-31 | Chimica Profarmaco Spa Ind | Processo di risoluzione ottica di acido 2 (6 metossi 2 naftil) propionico |
| US5225603A (en) | 1987-07-14 | 1993-07-06 | Hoechst Celanese Corporation | Preparation of 4-(6'-methoxy-2'-naphthyl)-3-buten-2-one |
| JP2518014B2 (ja) | 1988-05-31 | 1996-07-24 | 日産化学工業株式会社 | α−置換酢酸の精製方法 |
| GB8915104D0 (en) | 1989-06-30 | 1989-08-23 | Beecham Group Plc | Chemical process |
| NL9001703A (nl) | 1990-07-27 | 1992-02-17 | Westspur Investment Ltd | Werkwijze voor de bereiding van s(+)-6-methoxy-alfa-methyl-2-naftaleen-azijnzuur. |
| KR930003864B1 (ko) | 1990-10-19 | 1993-05-14 | 한국과학기술연구원 | d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법 |
| US5179208A (en) | 1990-10-19 | 1993-01-12 | Korea Institute Of Science And Technology | Process for preparing d-2-(6-methoxy-2-naphthyl)-propionic acid and intermediate thereof |
| DE69210323T3 (de) | 1991-07-31 | 1999-06-02 | Tessenderlo Chemie N.V., Bruxelles | Verfahren zur Alpha-Monoalkierung von Arylacetonitrilen, Arylacetoestern und Arylessigsäuren |
| US5248815A (en) | 1991-12-27 | 1993-09-28 | Paradies Henrich H | Stereo-selective synthesis of 2-aryl-propionic acids of high optical purity by using chiral oxazolines |
| GB9201857D0 (en) | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
| FR2686876B1 (fr) | 1992-02-04 | 1994-05-13 | Hoechst Ste Francaise | Procede de preparation d'acides arylacetiques et de leurs sels de metaux alcalins. |
| IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| US5223640A (en) | 1992-12-23 | 1993-06-29 | Hoechst Celanese Corporation | Preparation of optically active α-aryl propionic acids |
| GB9314693D0 (en) | 1993-07-15 | 1993-08-25 | Smithkline Beecham Plc | Naphthyl derivatives for treatment method |
| HU218923B (hu) | 1993-10-06 | 2000-12-28 | Nicox S.A. | Gyulladásgátló és/vagy fájdalomcsillapító hatású nitrát-észterek, ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására |
| RU2145595C1 (ru) | 1994-05-10 | 2000-02-20 | Никокс С.А. | Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности |
| US5426243A (en) | 1994-08-17 | 1995-06-20 | Albemarle Corporation | Process for preparing 1,6-dibromo-2-naphthylene compounds |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5600009A (en) | 1996-04-09 | 1997-02-04 | Hoechst Celanese Corporation | Use of 4-substituted 2-butanones to prepare nabumetone |
| AU7324696A (en) | 1995-11-17 | 1997-06-11 | Aeci Limited | Synthesis of propionic acid derivatives |
| IT1285567B1 (it) | 1996-02-21 | 1998-06-18 | Alfa Chem Ital | Nuovo processo per la sintesi del nabumetone |
| IT1282686B1 (it) | 1996-02-26 | 1998-03-31 | Nicox Sa | Composti in grado di ridurre la tossicita' da farmaci |
| IT1283638B1 (it) | 1996-07-29 | 1998-04-23 | Archimica Spa | Procedimento per la preparazione di un naftilbutanone |
| US5756851A (en) | 1996-10-21 | 1998-05-26 | Albemarle Corporation | Production of nabumetone or precursors thereof |
| US5792886A (en) | 1997-01-08 | 1998-08-11 | Albemarle Corporation | Production of racemic 2-(6-methoxy-2-naphthyl) propionic acid of precursors thereof |
| US5741938A (en) | 1997-02-21 | 1998-04-21 | Albemarle Corporation | Production of alkyl aralkyl keones from allylic-aralkenyl secondary alcohols |
| ATE231128T1 (de) * | 1997-02-21 | 2003-02-15 | Takeda Chemical Industries Ltd | Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung |
| US5847225A (en) | 1997-04-25 | 1998-12-08 | Albemarle Corporation | Production of naphthyl-substituted ketones from naphthaldehydes |
| IT1291284B1 (it) | 1997-04-30 | 1999-01-07 | Secifarma Spa | Processo per la preparazione del 4-(6'-metossi-2'-naftil)butan-2-one (nabumetone). |
| US5861538A (en) | 1997-08-04 | 1999-01-19 | Albemarle Corporation | Production of alkoxynaphthyl-substituted ketones from naphthaldehydes |
| US5874614A (en) | 1997-12-11 | 1999-02-23 | Albemarle Corporation | Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate |
| US6436990B1 (en) * | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
| US6552078B2 (en) * | 1999-10-27 | 2003-04-22 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| TWI262791B (en) * | 1999-10-27 | 2006-10-01 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
-
2000
- 2000-10-26 TW TW089122555A patent/TWI262791B/zh active
- 2000-10-27 EP EP00978284A patent/EP1223926A2/en not_active Withdrawn
- 2000-10-27 CZ CZ20021435A patent/CZ20021435A3/cs unknown
- 2000-10-27 JP JP2001532754A patent/JP2003512424A/ja active Pending
- 2000-10-27 AU AU15761/01A patent/AU1576101A/en not_active Abandoned
- 2000-10-27 IL IL14925800A patent/IL149258A0/xx unknown
- 2000-10-27 JP JP2001532758A patent/JP2003512425A/ja active Pending
- 2000-10-27 PL PL00354895A patent/PL354895A1/xx unknown
- 2000-10-27 CZ CZ20021433A patent/CZ20021433A3/cs unknown
- 2000-10-27 RU RU2002113657/15A patent/RU2002113657A/ru unknown
- 2000-10-27 EP EP00992732A patent/EP1223922A2/en not_active Withdrawn
- 2000-10-27 PL PL00354510A patent/PL354510A1/xx not_active Application Discontinuation
- 2000-10-27 CN CN00817761A patent/CN1413106A/zh active Pending
- 2000-10-27 AU AU29196/01A patent/AU2919601A/en not_active Abandoned
- 2000-10-27 MX MXPA02004355A patent/MXPA02004355A/es unknown
- 2000-10-27 WO PCT/US2000/029757 patent/WO2001030334A2/en not_active Application Discontinuation
- 2000-10-27 CA CA002387098A patent/CA2387098A1/en not_active Abandoned
- 2000-10-27 WO PCT/US2000/041692 patent/WO2001030338A2/en active IP Right Grant
- 2000-10-27 IL IL14925700A patent/IL149257A0/xx unknown
- 2000-10-27 CN CN00817762A patent/CN1413108A/zh active Pending
- 2000-10-27 KR KR1020027005358A patent/KR20020043249A/ko not_active Application Discontinuation
- 2000-10-27 KR KR1020027005356A patent/KR20020043248A/ko not_active Application Discontinuation
- 2000-10-27 BR BR0015121-1A patent/BR0015121A/pt not_active Application Discontinuation
- 2000-10-27 BR BR0015122-0A patent/BR0015122A/pt not_active Application Discontinuation
- 2000-10-27 HU HU0203321A patent/HUP0203321A2/hu unknown
- 2000-10-27 RU RU2002113661/15A patent/RU2002113661A/ru unknown
- 2000-10-27 MX MXPA02004357A patent/MXPA02004357A/es active IP Right Grant
- 2000-10-27 NZ NZ518554A patent/NZ518554A/en unknown
- 2000-10-27 CA CA002389181A patent/CA2389181A1/en not_active Abandoned
- 2000-10-27 US US09/697,795 patent/US6525098B1/en not_active Expired - Fee Related
- 2000-10-27 HU HU0203790A patent/HUP0203790A3/hu unknown
- 2000-10-27 NZ NZ518553A patent/NZ518553A/en unknown
-
2002
- 2002-04-23 ZA ZA200203231A patent/ZA200203231B/xx unknown
- 2002-04-23 ZA ZA200203229A patent/ZA200203229B/en unknown
- 2002-04-26 NO NO20022000A patent/NO20022000L/no not_active Application Discontinuation
- 2002-04-26 NO NO20022001A patent/NO20022001L/no not_active Application Discontinuation
- 2002-06-12 US US10/170,800 patent/US20030069309A1/en not_active Abandoned
-
2003
- 2003-01-16 HK HK03100399.4A patent/HK1048256A1/zh unknown
- 2003-01-16 HK HK03100400.1A patent/HK1048257A1/zh unknown
-
2004
- 2004-10-21 US US10/970,571 patent/US20050054735A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8569536B2 (en) | C-nitroso-derived nitroxyl donors | |
| US20100285074A1 (en) | Phenoxyalkylcarboxylic acid derivatives in the treatment of irritable bowel syndrome | |
| WO2001041704A2 (en) | Method for the prevention and/or treatment of atherosclerosis | |
| US6525098B1 (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
| US6436990B1 (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
| US20170151337A1 (en) | High penetration composition and uses thereof | |
| JP2005514352A6 (ja) | 自己免疫疾患の治療法 | |
| US6730701B2 (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
| AU2006200877A1 (en) | 6-Methoxy-2-Naphthylacetic Acid Prodrugs | |
| JPS60158149A (ja) | 炎症抑制作用を有する１，４‐ナフトキノン誘導体 | |
| US20220096370A1 (en) | High penetration composition and uses thereof | |
| JPS61129124A (ja) | 抗腫瘍剤 |